QLife

Pharmacies are expected to play an increasingly important role in healthcare, with blood testing now paving the way for faster, more accessible, and patient-centered diagnostics. With the strategic focus of public health management on bringing healthcare services closer to citizens, blood testing will become an integrated part of pharmacy offerings, especially in the management of common illnesses and chronic conditions.

"Based on our exclusive commercial agreement with Hipro Biotechnology we now have a significant portfolio of blood testing devices that can be easily operated in a pharmacy. We are inspired by the impact of the UK's Pharmacy First program and see a unique opportunity to help redefine the role of pharmacies in the Nordic healthcare system. We will soon start pilot projects with a number of pharmacies which marks the first step in bringing accessible and efficient blood testing to pharmacies, with a vision to expand across Denmark, Sweden, UK and ultimately all of EU." says Thomas Warthoe, CEO.

Background and Drivers
The expansion of POCT in pharmacies is driven by national strategies (as seen in the UK), an aging population, increased pressure on primary care, and technological advancements that have accelerated the need for rapid and precise testing options outside hospitals.

Impact on Public Health
The implementation of POCT has been shown to increase the diagnosis of, for example, cardiovascular diseases and diabetes, while simultaneously reducing unnecessary use of antibiotics. Studies show that the use of blood tests in pharmacies can halve antibiotic consumption in the treatment of acute sore throats compared to traditional pathways.

Clinical Benefits and Governance
Blood testing in pharmacies enables faster decision-making, fewer clinic visits, and better utilization of healthcare professionals' time. Services such as "Pharmacy First" in the UK and "Test and Treat" in the US have already helped hundreds of thousands of patients gain quick access to treatment. Clinical governance is ensured through clear procedures for training, quality assurance, and accountability, with the designated pharmacy lead holding overall responsibility.

For more information, please contact:

Thomas Warthoe, Chief Executive Officer (CEO)

Phn: +45 21 63 35 34

E-mail: tw@egoo.health

Qlife is a Swedish company based in Göteborg, which develops and markets an innovative medical technology platform, Egoo.Health ("Egoo"), with the goal of giving people access to clinical biomarker data when testing at home. The company is listed on the Nasdaq First North Growth Market (ticker: QLIFE). G&W Fondkommission is the Company's Certified Adviser. For additional information, please visit www.qlifeholding.com.